Press Enter to Main Content
:::
Patents

2026 TIPA International Symposium Focuses on European Patent Litigation and Global Pharmaceutical Shifts, Guiding New IP Strategies for Businesses

Font Size:

The 2026 TIPA International Symposium was held on October 30, 2026, at the International Conference Hall, Tsai Lecture Hall of the College of Law, National Taiwan University. The event was co-hosted by TIPO and the Judicial Yuan, and planned and organized by the Graduate Institute of Interdisciplinary Legal Studies of the NTU College of Law. Opening remarks were delivered by Justice and Acting President of the Judicial Yuan Ming-Yan Shieh, TIPO Director General Cheng-Wei Liao, Taiwan Bar Association Chairperson Ling-Ling Lee, and NTU College of Law Chair Professor Tsung-Fu Chen. The symposium drew more than 100 participants from industry, government, academia and research institutions.

The symposium centered on two core themes. The morning session, “EU Unitary Patent Litigation and Its Impact on Global Patent Portfolio Strategies,” featured a keynote speech by Tobias Pichlmaier, Presiding Judge at the District Court in Munich and Judge of the Unified Patent Court (UPC) Local Division in Munich. He shared first-hand insights into UPC adjudication practice and litigation trends. A highlight of the session was the roundtable discussion. It brought together a Division-Chief Judge of Taiwan’s Intellectual Property and Commercial Court (IPCC), representatives of renowned domestic and international law firms, and senior IP executives from MediaTek Inc. and AUO Corporation, two of Taiwan’s leading technology companies. Drawing on their front-line industry experience, the panelists examined patent defense and portfolio strategies across global supply chains.

The afternoon session addressed “Strategy of Market Positioning and Patent Protection in Pharmaceutical Industry Under the Shifting International Order.” In recent years, the U.S. government’s Most Favored Nation (MFN) drug pricing policy, pharmaceutical tariffs and the restructuring of global supply chains have profoundly affected the global pharmaceutical industry and drug markets. This session brought together partners from leading law firms in Taiwan and abroad for dialogue with representatives from industry, government and academia, including the National Health Insurance Administration (NHIA), the Taiwan Food and Drug Administration (TFDA), the International Research-Based Pharmaceutical Manufacturers Association (IRPMA), and the Taiwan Generic Pharmaceutical Association (TGPA).

Through presentations and discussions by IP experts from Taiwan, Europe and the United States, the symposium helped participants keep abreast of trends in European patent litigation and shifts in the global pharmaceutical landscape. The insights shared can also serve as a reference for the development of Taiwan’s patent system and practice.

  • Publish Date:2026/11/10
  • Update: 2026/11/10
  • Organization:International & Legal Affairs Office
  • Views:142
To the Top